The p73 protein is a transcription factor and member of the p53 protein family that expresses as a complex variety of isoforms. DNp73a is an N-terminally truncated isoform of p73. We found that DNp73 protein is upregulated in human gastric carcinoma suggesting that DNp73 may play an oncogenic role in these tumors. Although it has been shown that DNp73a inhibits apoptosis and counteracts the effect of chemotherapeutic drugs, the underlying mechanism by which this p73 isoform contributes to chemotherapeutic drug response remains to be explored. We found that DNp73a upregulates MDR1 mRNA and pglycoprotein (p-gp), which is involved in chemotherapeutic drug transport. This p-gp upregulation was accompanied by increased p-gp functional activity in gastric cancer cells. Our data suggest that upregulation of MDR1 by DNp73a is mediated by interaction with p53 at the MDR1 promoter.
Introduction
Gastric cancer is the second most common cause of death due to cancer worldwide (Parkin et al., 2005) . Resistance to chemotherapy is a major problem in treatment of gastric carcinomas. Tumor cells often acquire drug resistance phenotype through the upregulation of the mdr1 gene. A product of the mdr1 gene, p-glycoprotein (p-gp), is a 170-kDa transmembrane protein that functions as an energy-dependent drug efflux pump, the substrates of which include a wide range of anticancer drugs. MDR1 is often overexpressed in primary gastric adenocarcinoma and its precursor lesions (Vollrath et al., 1991; Wallner et al., 1993; Lacueva et al., 1998; Choi et al., 2002) . This increase in p-gp levels correlates with an increased resistance to the chemotherapeutic drug, doxorubicin, in primary gastric cancer cells (Hotta et al., 1999) .
Tumor-suppressor protein p53 regulates mdr1 gene expression. Wild-type p53 (wtp53) suppresses MDR1 promoter constructs, as well as expression of the endogenous mdr1 gene, whereas several common p53 mutants are able to activate the MDR1 promoter (Chin et al., 1992; Dittmer et al., 1993; Thottassery et al., 1997) .
Accumulating evidence suggests that p53 functions in concert with p73, another member of the p53 protein family. Extensive structural similarity exists between p53 and p73, but the highest is found in the DNA-binding domain, in which p73 shares approximately 60% aminoacid identity with p53. p73 is expressed as a complex variety of protein isoforms with and without N-terminal transactivation domain (TAD). Isoforms with TAD are termed TA, whereas isoforms without TAD are known as DN. TA isoforms of p73 transactivate p53 target genes and induce apoptosis (Kaghad et al., 1997) . In contrast, DNp73a inhibits apoptosis and confers drug resistance (Fillippovich et al., 2001; Zaika et al., 2002) . High expression levels of DNp73 significantly correlate with chemotherapeutic failure in ovarian cancer. Moreover, p53 is likely a main target of DNp73 in these tumors (Concin et al., 2005) . In mice, DNp73 features proto-oncogenic properties; it facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation and in tumorigenesis (Stiewe and Putzer, 2002; Petrenko et al., 2003) . Expression of DNp73 correlates with poor patient prognosis in neuroblastoma, lung, ovarian, prostate, colon and breast cancers (Casciano et al., 2002; Guan and Chen, 2005; Dominguez et al., 2006) .
In this study, we examined the role of p73 isoforms in regulation of mdr1 gene expression in gastric cancer cells.
Results

Expression of DNp73a in gastric carcinoma
Protein expression of DNp73 was evaluated in 48 gastric carcinomas and 88 non-neoplastic gastric specimens.
DNp73 immunoreactivity was found in both nuclei and cytoplasm of epithelial cells. However, intensity of DNp73 staining was weaker in non-neoplastic cells compared to that of tumor cells and was observed mostly in cytoplasm, whereas the tumor cells showed strong nuclear staining (Figure 1a ). We found a statistically significant increase (P ¼ 0.00014) in nuclear staining in the tumor samples compared to nonneoplastic mucosa (Figure 1b) . Nuclear overexpression of DNp73 protein was detected in 59% (26 of 44 cases) analysed tumors.
Pairwise comparison of 44 informative carcinoma cases with matched non-neoplastic mucosa also demonstrated a statistically significant (P ¼ 0.0011) increase in nuclear DNp73 staining in the tumors' epithelia ( Figure 1c) . Interestingly, an increase of DNp73 expression was significantly higher in intestinal-type gastric carcinoma (P ¼ 0.000015).
DNp73a upregulates mdr1 gene expression in gastric cancer cells To assess whether p73 affects mdr1 gene expression, AGS cells were transfected with plasmids expressing various p73 isoforms, and MDR1 mRNA levels were determined by real-time PCR analysis (Figure 2a ). MDR1 transcript level was increased more than 25-fold in DNp73a-transfected cells compared to vector control. In contrast to the DNp73a effect and in accord with previous reports (Chin et al., 1992; Thottassery et al., 1997) , wtp53 inhibited MDR1. Interestingly, mutant DNp73a (L322P) was unable to increase the MDR1 mRNA level. Similarly, TAp73a or TAp73b did not affect MDR1 transcription. To confirm these findings, MDR1 promoter fragment (À1277 to þ 25) was cloned into pGL3 luciferase reporter vector, and luciferase assay was performed in AGS cells. As shown in Figure 2b , MDR1 promoter activity increased in cells expressing DNp73a compared to empty-vector transfected cells. Transfection of wtp53 led to a decrease in MDR1 promoter activity. Notably, TAp73a and TAp73b were able to activate the reporter, although at lower levels than DNp73a. Most likely, the observed difference in activation of mdr1 gene transcription by To determine whether DNp73a upregulates p-gp, we performed western blot analysis with a p-gp-specific antibody. As a positive control, cells transfected with To further confirm these data, an AGS stable cell line expressing DNp73a in a doxycycline-inducible manner was generated. Using western blot analysis, we found that the induction of DNp73a increases the level of p-gp ( Figure 2d ). An exposure of a parental AGS cell line to the same concentration of doxycycline did not affect the p-gp expression (data not shown).
DNp73a causes the increase in p-gp transporter activity in gastric cancer cells Next, changes in MDR1 functional activity were measured by the calcein uptake assay using two wellknown MDR1 inhibitors verapamil and cyclosporine A. We observed a significant increase in the p-gp activity in AGS cells expressing DNp73a compared to control cells transfected with vector alone (Figures 3a and b) . Interestingly, TAp73a was unable to elevate the p-gp transporter activity (data not shown). These results demonstrate that DNp73a increases calcein extrusion, thus suggesting that the observed upregulation of mdr1 gene expression correlates with the increase in p-gp transporter activity.
Activation of the mdr1 gene expression by DNp73a depends on p53 activity Similar to the experiment with AGS cells described above, we evaluated the effect of DNp73a on MDR1 expression in additional cell lines having different p53 statuses. Surprisingly, endogenous MDR1 mRNA was increased only in cells expressing wtp53 (AGS and U2OS; Figures 2a and 4c) ; whereas, no upregulation was detected in p53-null (H1299) or p53-mutant (Caco-2) cells (Figures 4a and b) . HeLa cells, which express very low levels of p53 due to the presence of HPV E6 protein (Hoppe-Seyler and Butz, 1993) were also nonresponsive to DNp73a transfection (data not shown), indicating that p53 is involved in the regulation of MDR1 expression by DNp73a.
To assess the role of p53, MDR1 luciferase assay was performed in AGS cells transfected with p53 and DNp73a in combination or alone. DNp73a activity was abrogated by transfection of wtp53 (Figure 5a ). Thus, p53 counteracts DNp73a function on MDR1 promoter. Equal expression of DNp73a and p53 in this experiment was To further confirm these data, we investigated whether wtp53 would have a similar effect on endogenous MDR1 mRNA levels. Likewise to the luciferase experiment described above, p53 completely suppressed upregulation of MDR1 mRNA induced by DNp73a (Figure 5b ). Next, we co-transfected AGS cells with DNp73a or pcDNA3 and either small interfering RNA (siRNA) specific for p53 (p53 siRNA) or nonspecific dsRNA (sc.RNA). A decrease in the endogenous p53 protein level caused by p53 siRNA led to a further increase of DNp73a activity, and endogenous MDR1 mRNA compared to cells co-transfected with DNp73a and unspecific dsRNA (Figure 5c ). The efficiency of p53 inhibition by siRNA and equal expression of DNp73a were confirmed by western blotting (Figure 5c , lower panel). Interestingly, downregulation of p53 alone did not result in a significant increase of mdr1 gene expression suggesting that DNp73a is essential for full activation of the MDR1 promoter ( Figure 5c ). Previously, it has been reported that p53 binds to the MDR1 promoter (Johnson et al., 2001) . Therefore, we examined the effect of DNp73a on DNAbinding of p53 using chromatin immunoprecipitation (ChIP). Our ChIP analysis confirmed that endogenous p53 specifically binds to the MDR1 promoter in AGS cells (Figure 5d , lane 3). Transfection of DNp73a led to a significant decrease of p53 binding to the same promoter ( Figure 5d , compare lanes 3 and 4). A similar effect was observed in AGS cells expressing DNp73a in a tetinducible manner (data not shown). The ChIP assay also revealed that DNp73a binds to the MDR1 promoter ( Figure 5e , lane 3).
Discussion
In this study, we investigated expression of the p73 isoform, DNp73, in gastric cancer. Using an immunohistochemical approach, we found that the DNp73 protein expression is significantly increased in the gastric carcinoma as compared to non-neoplastic gastric mucosa. Elevated DNp73 staining was observed in the nuclei of cancer cells primarily in intestinal-type tumors. This increase is consistent with reports by us and others, which suggest that DNp73a has oncogenic and antiapoptotic properties (Stiewe and Putzer, 2002; Zaika et al., 2002; Petrenko et al., 2003) . Several studies have also shown that DNp73 may contribute to drug resistance in vitro and in vivo (Vossio et al., 2002; Zaika et al., 2002; Uramoto et al., 2004; Concin et al., 2005) . These findings raise an important question about targets of DNp73. Here, we provide proof of a novel link between DNp73a and upregulation of one of the major markers of drug resistance, MDR1. We found that DNp73a upregulates endogenous MDR1 mRNA and protein in gastric epithelial cells. Furthermore, upregulation of p-gp by DNp73a correlates with an increase of its transporter activity. A recent study has found upregulation of MDR1 mRNA by TAp73 isoforms in neuroblastoma cells (Johnson et al., 2005) . We did not observe this phenomenon in this study, which suggests that the p73 effect might be cellline dependent. Indeed, we found DNp73-induced upregulation only in cell lines with wtp53 (see Figure 4) . Interestingly, DNp73a(L322P) mutant, which has an impaired ability to inhibit p53, was unable to activate mdr1 gene transcription (Zaika et al., 2002) . This finding points to p53's role in the regulation of MDR1 by DNp73a. We explored this hypothesis further and found that co-transfection of DNp73a together with wtp53 leads to suppression of the mdr1 gene expression induced DNp73a. Inversely, inhibition of endogenous p53 by siRNA increased MDR1 mRNA accumulation in response to DNp73a. Thus, DNp73-induced upregulation of MDR1 is controlled by p53.
Depending on the target gene, p53 usually acts either as a transcriptional activator or repressor (Vousden, 2006) . In the contest of the mdr1 gene, p53 suppresses mdr1 gene transcription through a direct binding to its promoter (Johnson et al., 2001) . The transcriptional inhibition of MDR1 expression by p53 was also confirmed in this study (see Figures 2a and b) . We and others also found that DNp73 physically interacts with p53 (Pozniak et al., 2000; Nakagawa et al., 2002; Zaika et al., 2002) . In addition, our ChIP analysis revealed that upregulation of DNp73a interferes with p53-specific binding to the MDR1 promoter (see Figure 5d) . However, the data also showed that downregulation of p53 alone is not sufficient to upregulate MDR1, and DNp73a is required for full activation of the MDR1 transcription. Using ChIP, we found that DNp73a binds to the MDR1 promoter. These data combined with the recent characterization of a novel transactivation domain in DNp73 (Liu et al., 2004) suggests that DNp73 may function as a transcription factor.
In summary, the results demonstrate that DNp73a activates mdr1 gene expression and increases p-gp transporter activity in gastric cancer cells. This activation resulted from inhibition of p53 activity and DNp73 binding to the MDR1 promoter. These data provide the first evidence that DNp73a compromises p53 function as a repressor and reveal a novel mechanism that may underlie drug resistance in gastric tumors.
Materials and methods
Tissue sample, tissue array construction and immunohistochemistry After the institutional review board approval, 48 carcinoma cases with matched non-neoplastic mucosa and 40 additional non-neoplastic gastric samples resected at Vanderbilt University Medical Center were histologically verified and representative regions were selected for inclusion in a tissue microarray.
For immunohistochemical staining, slides were pretreated in citrate buffer in a pressure cooker. Anti-DNp73 antibody (Imgenex, San Diego, CA, USA) was applied at room temperature and immunostaining was detected using EnVision þ HRP kit (DakoCytomation, Ely, Cambridgeshire, UK). This antibody recognizes the unique epitope located on the N-terminus of DNp73 and does not crossreact with TAp73. Specificity of DNp73 staining was verified by omitting a primary antibody DNp73a regulates MDR1 expression by inhibiting p53 function A Vilgelm et al step in the protocol. The nuclei were counterstained with hematoxylin. Immunohistochemical results were evaluated for intensity and staining frequency in nuclear and cytoplasmic compartments. The intensity of staining was graded as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). The frequency was graded according to the percentage of positive cells. Total nuclear and cytoplasmic scores were calculated by multiplying the intensity score by the percentage of positive cells.
Cell culture and generation of DNp73a-Tet-on cells AGS cells were maintained in Ham's F-12 media (Invitrogen, Carlsbad, CA, USA). U2OS, Caco-2 and H1299 cell lines were grown in Dulbecco's modified Eagle's medium (Invitrogen). Culture media were supplemented with 10% fetal bovine serum.
To generate cells expressing DNp73a in a doxycyclineinducible manner, 1.8 Kb NotI-ClaI fragment containing flagDNp73a was subcloned into the pTRE2pur vector (Clontech, Palo Alto, CA, USA). AGS Tet-on cells (Clontech) were transfected with DNp73a-pTRE2pur and selected with puromycin according to the manufacturer's protocol.
Vectors, antibodies, transfection and luciferase assay pcDNA3-based vectors expressing human p53, p73a, p73b, DNp73a and tetramerization domain mutant, DNp73L322P, have been described previously (Zaika et al., 2002; Tomkova et al., 2006) . pMDR1-luc reporter plasmid was constructed by insertion of MDR1 promoter fragment generated by PCR (À1277 to þ 25) into pGL3 luciferase vector (Promega, Madison, WI, USA). Cells were transfected with LipofectA-MINE 2000 (Invitrogen) or FuGENE 6 (Roche, Indianapolis, IN, USA) reagents using the manufacturers' protocols. Target proteins were detected using specific antibodies: MDR1 (Sigma, St Louis, MO, USA), p53 (DO-1, Calbiochem, La Jolla, CA, USA), anti-Flag (M2, Sigma) and actin (Cell Signaling, Danvers, MA, USA). Luciferase activity was measured using a Dual-Luciferase Reporter Assay kit (Promega) as described earlier (Tomkova et al., 2004) . All experiments were performed in triplicate. Data is presented as average7s.d.
RNA isolation and real-time PCR analysis
Total RNA was extracted using Trizol (Invitrogen). Reverse transcription was performed using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Quantitative real-time PCR was carried out using an iCycler (Bio-Rad). The PCR primers were as follows: MDR1 forward, 5 0 -GGG TGG TGT CAC AGG AAG AG-3 0 , and MDR1 reverse, 5 0 -AAC AAG GGC ACG AGC TAT GG-3 0 ; HPRT forward, 5 0 -TTG GAA AGG GTG TTT ATT CCT CA-3 0 , and HPRT reverse, 5 0 -TCC AGC AGG TCA GCA AAG AA-3 0 . All reactions were performed in duplicate. The expression level of MDR1 mRNA was normalized to HPRT1 mRNA expression. Data is shown as fold expression 7s.d. compared to corresponding controls.
Small interfering RNA AGS cells were co-transfected with DNp73a or pcDNA3 and either siRNA oligonucleotide specific for human p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or unspecific control dsRNA (Ambion, Austin, TX, USA).
p-gp functional activity p-gp activity was assessed using Vybrant Multidrug Resistance Assay Kit (Molecular Probes, Invitrogen). p-gp activation was quantified by measuring an increase in intracellular calcein-AM fluorescence after exposure to MDR1 inhibitors. Briefly, AGS cells were grown in 96-well plates, transfected with indicated plasmids and allowed to recover. After 24 h, the medium was aspirated and cells were preincubated with either phosphate buffered saline or phosphate buffered saline supplemented with MDR1 inhibitor verapamil (100 mM) or cyclosporin A (10 mM) for 30 min at 37 1C. Calcein-AM was then added to the cells at final concentration 0.4 mM and the plates were incubated for 1 h at 37 1C. Calcein-AM containing solutions were replaced with ice-cold phosphate buffered saline and fluorescence was measured using a microplate reader. Experiments were conducted in six parallel wells and results were normalized for protein concentration. Data are presented as average7s.e.
Chromatin immunoprecipitation
ChIP analysis was performed in AGS cells (either transfected with flag-tagged DNp73 or expressing DNp73 in a tet-inducible manner and corresponding control cells) using the ChIP assay kit (Upstate Biotechnology, Lake Placid, NY, USA) as described earlier (Tomkova et al., 2006) . Bindings of p53 and DNp73 to the MDR1 promoter were analysed by PCR using following primers: 5 0 -ACCTGTTTCGCAGTTTCTCG-3 0 and 5 0 -AAGAGCCGCTACTCGAATGA-3 0 . The control primers, 5 0 -AGAGAGGGGCACAGCACTAA-3 0 and 5 0 -GGCAAGC TATCCAGGCAATA-3 0 , were used to amplify unspecific DNA (darpp32 gene). PCR conditions were as follows: 94 1C for 1 min, 55 1C for 1 min, and 72 1C for 1 min for 35 cycles and a final extension for 7 min at 72 1C. PCR products were separated on 1.5% agarose gel and visualized with ethidium bromide.
Statistical analysis
Wilcoxon rank sum test was used for non-pairwise comparison of gastric carcinoma and non-neoplastic mucosa samples. Wilcoxon signed rank test was used for pairwise comparison of matching tumor and normal cases. Pp0.05 were considered statistically significant.
